BioNexus Gene Lab Corp (BGLC) Q1 2026 Annual Earnings
BGLC·Reported May 15, 2026·Before market open
BioNexus Gene Lab Corp reported Q1 2026 revenue of $22.8K (-98.9% YoY). Diluted EPS came in at $-0.23 (-666.7% YoY).
Revenue
$22.8K
Diluted EPS
$-0.23
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about BioNexus Gene Lab Corp's Q1 2026 earnings report.
BioNexus Gene Lab Corp (BGLC) reported Q1 2026 earnings on May 15, 2026 before market open.
BioNexus Gene Lab Corp reported revenue of $22.8K and diluted EPS of $-0.23 for Q1 2026.
Compared to the same quarter a year prior, revenue declined 98.9% from $2.1M a year earlier and diluted EPS declined 666.7% from $-0.03.
You can read the 10-K periodic report (0001477932-26-002218) directly on SEC EDGAR. The filing index links above go to sec.gov.